{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:27:09Z","timestamp":1786991229883,"version":"build-2736575974"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"vor","delay-in-days":3155,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1016\/j.jacc.2004.09.049","type":"journal-article","created":{"date-parts":[[2004,12,31]],"date-time":"2004-12-31T07:45:15Z","timestamp":1104479115000},"page":"1-9","source":"Crossref","is-referenced-by-count":25,"title":["Ximelagatran: Oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation"],"prefix":"10.1016","volume":"45","author":[{"given":"Jonathan L.","family":"Halperin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2004.09.049_bib1","doi-asserted-by":"crossref","first-page":"194S","DOI":"10.1378\/chest.119.1_suppl.194S","article-title":"Antithrombotic therapy in atrial fibrillation","volume":"119","author":"Albers","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2004.09.049_bib2","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMp038123","article-title":"Atrial fibrillation and stroke prevention","volume":"349","author":"Hart","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2004.09.049_bib3","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1053\/apmr.2000.6981","article-title":"Functional outcome in stroke patients with atrial fibrillation","volume":"81","author":"Karatas","year":"2000","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.jacc.2004.09.049_bib4","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000068743","article-title":"Atrial fibrillation is associated with severe acute ischemic stroke","volume":"22","author":"Dulli","year":"2003","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.jacc.2004.09.049_bib5","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1161\/01.STR.0000035735.49388.4A","article-title":"Atrial fibrillation, stroke, and acute antithrombotic therapy: analysis of randomized clinical trials","volume":"33","author":"Hart","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2004.09.049_bib6","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1161\/01.CIR.0000140263.20897.42","article-title":"Lifetime risk for development of atrial fibrillation: the Framingham Heart study","volume":"110","author":"Lloyd-Jones","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2004.09.049_bib7","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults\u2014national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2004.09.049_bib8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1136\/hrt.2003.014720","article-title":"Atrial fibrillation: an emerging epidemic?","volume":"90","author":"Steinberg","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2004.09.049_bib9","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/hrt.2002.008748","article-title":"Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK","volume":"90","author":"Stewart","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2004.09.049_bib10","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0735-1097(01)01587-X","volume":"38","author":"Fuster","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2004.09.049_bib11","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/archinte.1994.00420130036007","article-title":"Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials","volume":"154","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2004.09.049_bib12","doi-asserted-by":"crossref","unstructured":"Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492\u2013501.","DOI":"10.7326\/0003-4819-131-7-199910050-00003"},{"key":"10.1016\/j.jacc.2004.09.049_bib13","doi-asserted-by":"crossref","unstructured":"Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med 1999;131:688\u201395.","DOI":"10.7326\/0003-4819-131-9-199911020-00010"},{"key":"10.1016\/j.jacc.2004.09.049_bib14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/archinte.164.1.55","article-title":"National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation","volume":"164","author":"Fang","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2004.09.049_bib15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/j.1875-9114.1995.tb04379.x","article-title":"Bioequivalence and narrow therapeutic index drugs","volume":"15","author":"Benet","year":"1995","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jacc.2004.09.049_bib16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0049-3848(98)00213-8","article-title":"Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat","volume":"94","author":"Elg","year":"1999","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2004.09.049_bib17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0049-3848(00)00399-6","article-title":"The direct thrombin inhibitor melagatran and its oral prodrug H 376\/95: intestinal absorption properties, biochemical and pharmacodynamic effects","volume":"101","author":"Gustafsson","year":"2001","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2004.09.049_bib18","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nrd1466","article-title":"A new oral anticoagulant: the 50-year challenge","volume":"3","author":"Gustafsson","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jacc.2004.09.049_bib19","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1124\/dmd.31.3.294","article-title":"Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans","volume":"31","author":"Eriksson","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jacc.2004.09.049_bib20","unstructured":"Cohen AT, Agnelli G, Dahl OE, et al. Efficacy and safety of the treatment regimen of melagatran and ximelagatran for prevention of thromboembolic events after total hip or knee replacement: a meta-analysis of 3 randomized, double-blind studies, to evaluate the influence of time and dose (abstr CD-ROM). J Thromb Haemost 2003;1 Suppl 1."},{"key":"10.1016\/j.jacc.2004.09.049_bib21","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1001\/archinte.161.18.2215","article-title":"Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study","volume":"161","author":"Heit","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2004.09.049_bib22","doi-asserted-by":"crossref","first-page":"648","DOI":"10.7326\/0003-4819-137-8-200210150-00008","article-title":"Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind trial","volume":"137","author":"Francis","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2004.09.049_bib23","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1046\/j.1538-7836.2003.00368.x","article-title":"Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement: a randomized, double-blind study","volume":"1","author":"Colwell","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2004.09.049_bib24","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1056\/NEJMoa035162","article-title":"Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement","volume":"349","author":"Francis","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2004.09.049_bib25","unstructured":"Colwell CW, Berkowitz SD, Comp PC, et al. Randomized, double-blind comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR): EXULT B (abstr). Blood 2003;102. Online only. Available at: http:\/\/www.abstracts2view.com\/hem\/."},{"key":"10.1016\/j.jacc.2004.09.049_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1046\/j.1538-7836.2003.00034.x","article-title":"A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I","volume":"1","author":"Eriksson","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2004.09.049_bib27","first-page":"6a","article-title":"Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolism: the THRIVE treatment study","volume":"102","author":"Francis","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2004.09.049_bib28","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0140-6736(03)14287-0","article-title":"Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial","volume":"362","author":"Wallentin","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2004.09.049_bib29","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1159\/000073849","article-title":"Effects of the oral direct thrombin inhibitor ximelagatran on P-selectin expression and thrombin generation in atrial fibrillation","volume":"33","author":"Wolzt","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1016\/j.jacc.2004.09.049_bib30","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00228-003-0667-2","article-title":"Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and healthy subjects","volume":"59","author":"Wolzt","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl 2","key":"10.1016\/j.jacc.2004.09.049_bib31","first-page":"56","article-title":"Predictable pharmacokinetics of ximelagatran, an oral direct thrombin inhibitor, in nonvalvular atrial fibrillation patients receiving long-term treatment","volume":"32","author":"Eriksson","year":"2002","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1016\/j.jacc.2004.09.049_bib32","first-page":"31","article-title":"Pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation receiving long-term treatment: a population analysis by nonlinear mixed effect modeling","volume":"71","author":"Grind","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2004.09.049_bib33","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0049-3848(03)00249-4","article-title":"The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review","volume":"109","author":"Gustafsson","year":"2003","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2004.09.049_bib34","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2165\/00003088-200342080-00005","article-title":"Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions","volume":"42","author":"Bredberg","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jacc.2004.09.049_bib35","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00228-003-0619-x","article-title":"Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid","volume":"59","author":"Fager","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2004.09.049_bib36","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1177\/0091270004268048","article-title":"No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers","volume":"44","author":"Sarich","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2004.09.049_bib37","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1177\/0091270004268047","article-title":"No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran","volume":"44","author":"Sarich","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2004.09.049_bib38","first-page":"78","article-title":"Effect of erythromycin on the pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran and its active form melagatran","volume":"75","author":"Dorani","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2004.09.049_bib39","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00003088-200342040-00006","article-title":"Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor","volume":"42","author":"Johansson","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jacc.2004.09.049_bib40","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2165\/00003088-200342050-00005","article-title":"No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers","volume":"42","author":"Johansson","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jacc.2004.09.049_bib41","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2165\/00003088-200342050-00006","article-title":"No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran","volume":"42","author":"Sarich","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jacc.2004.09.049_bib42","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00228-003-0565-7","article-title":"Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects","volume":"59","author":"Eriksson","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2004.09.049_bib43","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/0091270004263649","article-title":"The pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol","volume":"44","author":"Sarich","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2004.09.049_bib44","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/S0735-1097(03)00255-9","article-title":"Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation","volume":"41","author":"Petersen","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2004.09.049_bib45","unstructured":"Petersen P. A 2-year follow-up of ximelagatran as an oral anticoagulant for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (abstr). Neurology 2002;58 Suppl 3:A477."},{"key":"10.1016\/j.jacc.2004.09.049_bib46","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0002-8703(03)00325-9","article-title":"Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V)","volume":"146","author":"Halperin","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2004.09.049_bib47","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(03)14841-6","article-title":"Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial","volume":"362","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2004.09.049_bib48","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0140-6736(04)15680-8","article-title":"Ximelagatran or warfarin in atrial fibrillation","volume":"363","author":"Olsson","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2004.09.049_bib49","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/S0140-6736(04)16470-2","article-title":"Aspirin bias in SPORTIF III trial","volume":"363","author":"Vadivelu","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2004.09.049_bib50","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/S0140-6736(04)16472-6","article-title":"Aspirin bias in SPORTIF III trial","volume":"363","author":"Olsson","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2004.09.049_bib51","unstructured":"Albers GW, for the Executive Steering Commitee on behalf of the SPORTIF Investigators. Pooled analysis of the SPORTIF III and V trials: secondary stroke prevention and stroke subtypes (abstr). Stroke 2004;35:242\u20133."},{"key":"10.1016\/j.jacc.2004.09.049_bib52","first-page":"2723","article-title":"Efficacy and safety study of the oral direct thrombin inhibitor ximelagatran compared with dose-adjusted warfarin in the prevention of stroke and systemic embolic events in patients with atrial fibrillation (SPORTIF V)","volume":"108","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2004.09.049_bib53","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1161\/01.STR.0000115528.53718.1B","article-title":"Ximelagatran or warfarin for stroke prevention in patients with atrial fibrillation?","volume":"35","author":"Hankey","year":"2004","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2004.09.049_bib54","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1474-4422(04)00738-0","article-title":"Warfarin for atrial fibrillation: the end of an era?","volume":"3","author":"Donnan","year":"2004","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jacc.2004.09.049_bib55","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/S0140-6736(03)14880-5","article-title":"Can we pull the plug on warfarin in atrial fibrillation?","volume":"362","author":"Verheugt","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2004.09.049_bib56","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jacc.2003.11.028","article-title":"Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation","volume":"43","author":"Rockson","year":"2004","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109704019424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109704019424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T15:39:38Z","timestamp":1705505978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109704019424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["S0735109704019424"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2004.09.049","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}